Antonio Rueda-Dominguez - Publications

Circulating immune and biochemical markers predict tumor response to immunotherapy in advanced melanoma and lung cancer.

Journal: Frontiers in immunology

Published: April 13, 2026

Integrating tumor and immune cell transcriptomics to predict immune checkpoint inhibitor primary resistance in metastatic melanoma.

Journal: Oncoimmunology

Published: March 31, 2026

Evolutionary and resistance dynamics in oligometastatic and oligoprogressive cancer treated with stereotactic radiotherapy and systemic therapies: A systematic review and focused meta-analysis.

Journal: Seminars in cancer biology

Published: February 28, 2026

SEOM-TTCC clinical guideline for nasopharyngeal carcinoma (update 2025).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: January 19, 2026

Association of IL7 rs16906115 Polymorphism with Immune-Related Adverse Events in Patients with Advanced Lung Cancer Undergoing Immunotherapy.

Journal: Journal of clinical medicine

Published: January 09, 2026

Prospective germline exome and machine learning-based risk score identify predictive and prognostic biomarkers of immunotherapy outcomes in advanced non-small cell lung cancer.

Journal: Journal of translational medicine

Published: January 08, 2026

The landscape of clonal hematopoiesis of indeterminate potential in long-term breast cancer survivors.

Journal: Breast (Edinburgh, Scotland)

Published: January 07, 2026

Integrative multiomic profiling of cfDNA methylation and EV-miRNAs identifies immunotherapy-outcome molecular subtypes in NSCLC.

Journal: Journal for immunotherapy of cancer

Published: January 01, 2026

Contrasting outcomes of inherited NOD2 loss-of-function variants on immunotherapy response in cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: December 05, 2025

Comparative effectiveness of two alternative dosing strategies of pembrolizumab in metastatic non-small-cell lung cancer in a real-world setting.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 06, 2025

High leptin levels independent of body mass index are associated with inflammation and poorer treatment response in patients with diffuse large B-cell lymphoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: October 01, 2025

SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: September 25, 2025